Financhill
Sell
22

BNTX Quote, Financials, Valuation and Earnings

Last price:
$91.38
Seasonality move :
15.46%
Day range:
$84.47 - $92.65
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
7.00x
P/B ratio:
1.03x
Volume:
951.6K
Avg. volume:
948.6K
1-year change:
-2.98%
Market cap:
$20.8B
Revenue:
$3B
EPS (TTM):
-$3.00

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BNTX
BioNTech SE
$172.7M -$2.18 7.26% -26.75% $138.37
CVAC
CureVac NV
$14.8M -$0.18 -72.17% -70.27% $7.42
GSK
GSK PLC
$9.8B $0.98 3.46% 52.75% $43.55
MRNA
Moderna
$130.3M -$3.10 -19.37% -0.05% $52.35
NVAX
Novavax
$71.8M $0.54 -23.54% -50.48% $16.43
SNY
Sanofi SA
$10.7B $0.92 -15.85% 82.5% $63.84
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BNTX
BioNTech SE
$86.65 $138.37 $20.8B 191.55x $0.00 0% 7.00x
CVAC
CureVac NV
$2.72 $7.42 $610.2M 4.96x $0.00 0% 1.02x
GSK
GSK PLC
$34.13 $43.55 $69.5B 21.56x $0.40 4.56% 1.76x
MRNA
Moderna
$24.64 $52.35 $9.5B -- $0.00 0% 2.99x
NVAX
Novavax
$6.33 $16.43 $1B -- $0.00 0% 1.45x
SNY
Sanofi SA
$49.86 $63.84 $125B 19.96x $2.04 7.9% 2.60x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BNTX
BioNTech SE
1.29% 1.937 0.97% 7.26x
CVAC
CureVac NV
-- 2.449 -- 6.10x
GSK
GSK PLC
53.74% -0.068 29.19% 0.49x
MRNA
Moderna
-- 0.004 -- 3.45x
NVAX
Novavax
-37.36% 8.675 13.16% 0.89x
SNY
Sanofi SA
17.11% 0.103 13.73% 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BNTX
BioNTech SE
$1B $924.4M -3.35% -3.39% 25.13% -$605.5M
CVAC
CureVac NV
$519.1M $404.1M 21.3% 21.3% 75.06% $381.2M
GSK
GSK PLC
$7.1B $2.8B 8.51% 19.22% 8.71% $1.5B
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
NVAX
Novavax
$51.6M -$131.1M -- -- -74.73% -$175.4M
SNY
Sanofi SA
$5.7B $917.8M 6.07% 7.55% 4.64% -$498.5M

BioNTech SE vs. Competitors

  • Which has Higher Returns BNTX or CVAC?

    CureVac NV has a net margin of 21.81% compared to BioNTech SE's net margin of 68.44%. BioNTech SE's return on equity of -3.39% beat CureVac NV's return on equity of 21.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    79.54% $1.15 $20.5B
    CVAC
    CureVac NV
    95.56% $1.65 $809.4M
  • What do Analysts Say About BNTX or CVAC?

    BioNTech SE has a consensus price target of $138.37, signalling upside risk potential of 59.69%. On the other hand CureVac NV has an analysts' consensus of $7.42 which suggests that it could grow by 172.86%. Given that CureVac NV has higher upside potential than BioNTech SE, analysts believe CureVac NV is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 4 0
    CVAC
    CureVac NV
    2 2 0
  • Is BNTX or CVAC More Risky?

    BioNTech SE has a beta of 1.069, which suggesting that the stock is 6.943% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BNTX or CVAC?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or CVAC?

    BioNTech SE quarterly revenues are $1.3B, which are larger than CureVac NV quarterly revenues of $543.2M. BioNTech SE's net income of $276.6M is lower than CureVac NV's net income of $371.8M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while CureVac NV's PE ratio is 4.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.00x versus 1.02x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    7.00x 191.55x $1.3B $276.6M
    CVAC
    CureVac NV
    1.02x 4.96x $543.2M $371.8M
  • Which has Higher Returns BNTX or GSK?

    GSK PLC has a net margin of 21.81% compared to BioNTech SE's net margin of 5.1%. BioNTech SE's return on equity of -3.39% beat GSK PLC's return on equity of 19.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    79.54% $1.15 $20.5B
    GSK
    GSK PLC
    68.47% $0.26 $36.4B
  • What do Analysts Say About BNTX or GSK?

    BioNTech SE has a consensus price target of $138.37, signalling upside risk potential of 59.69%. On the other hand GSK PLC has an analysts' consensus of $43.55 which suggests that it could grow by 27.59%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 4 0
    GSK
    GSK PLC
    2 3 1
  • Is BNTX or GSK More Risky?

    BioNTech SE has a beta of 1.069, which suggesting that the stock is 6.943% more volatile than S&P 500. In comparison GSK PLC has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.135%.

  • Which is a Better Dividend Stock BNTX or GSK?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GSK PLC offers a yield of 4.56% to investors and pays a quarterly dividend of $0.40 per share. BioNTech SE pays -- of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNTX or GSK?

    BioNTech SE quarterly revenues are $1.3B, which are smaller than GSK PLC quarterly revenues of $10.4B. BioNTech SE's net income of $276.6M is lower than GSK PLC's net income of $530.1M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while GSK PLC's PE ratio is 21.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.00x versus 1.76x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    7.00x 191.55x $1.3B $276.6M
    GSK
    GSK PLC
    1.76x 21.56x $10.4B $530.1M
  • Which has Higher Returns BNTX or MRNA?

    Moderna has a net margin of 21.81% compared to BioNTech SE's net margin of -117.16%. BioNTech SE's return on equity of -3.39% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    79.54% $1.15 $20.5B
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About BNTX or MRNA?

    BioNTech SE has a consensus price target of $138.37, signalling upside risk potential of 59.69%. On the other hand Moderna has an analysts' consensus of $52.35 which suggests that it could grow by 112.47%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 4 0
    MRNA
    Moderna
    5 17 1
  • Is BNTX or MRNA More Risky?

    BioNTech SE has a beta of 1.069, which suggesting that the stock is 6.943% more volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

  • Which is a Better Dividend Stock BNTX or MRNA?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or MRNA?

    BioNTech SE quarterly revenues are $1.3B, which are larger than Moderna quarterly revenues of $956M. BioNTech SE's net income of $276.6M is higher than Moderna's net income of -$1.1B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.00x versus 2.99x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    7.00x 191.55x $1.3B $276.6M
    MRNA
    Moderna
    2.99x -- $956M -$1.1B
  • Which has Higher Returns BNTX or NVAX?

    Novavax has a net margin of 21.81% compared to BioNTech SE's net margin of -91.76%. BioNTech SE's return on equity of -3.39% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    79.54% $1.15 $20.5B
    NVAX
    Novavax
    58.48% -$0.51 -$454.2M
  • What do Analysts Say About BNTX or NVAX?

    BioNTech SE has a consensus price target of $138.37, signalling upside risk potential of 59.69%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 159.54%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 4 0
    NVAX
    Novavax
    3 2 0
  • Is BNTX or NVAX More Risky?

    BioNTech SE has a beta of 1.069, which suggesting that the stock is 6.943% more volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

  • Which is a Better Dividend Stock BNTX or NVAX?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or NVAX?

    BioNTech SE quarterly revenues are $1.3B, which are larger than Novavax quarterly revenues of $88.3M. BioNTech SE's net income of $276.6M is higher than Novavax's net income of -$81M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.00x versus 1.45x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    7.00x 191.55x $1.3B $276.6M
    NVAX
    Novavax
    1.45x -- $88.3M -$81M
  • Which has Higher Returns BNTX or SNY?

    Sanofi SA has a net margin of 21.81% compared to BioNTech SE's net margin of 6.54%. BioNTech SE's return on equity of -3.39% beat Sanofi SA's return on equity of 7.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    79.54% $1.15 $20.5B
    SNY
    Sanofi SA
    70.24% $0.29 $97.7B
  • What do Analysts Say About BNTX or SNY?

    BioNTech SE has a consensus price target of $138.37, signalling upside risk potential of 59.69%. On the other hand Sanofi SA has an analysts' consensus of $63.84 which suggests that it could grow by 28.04%. Given that BioNTech SE has higher upside potential than Sanofi SA, analysts believe BioNTech SE is more attractive than Sanofi SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 4 0
    SNY
    Sanofi SA
    5 2 0
  • Is BNTX or SNY More Risky?

    BioNTech SE has a beta of 1.069, which suggesting that the stock is 6.943% more volatile than S&P 500. In comparison Sanofi SA has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.246%.

  • Which is a Better Dividend Stock BNTX or SNY?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 7.9% to investors and pays a quarterly dividend of $2.04 per share. BioNTech SE pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNTX or SNY?

    BioNTech SE quarterly revenues are $1.3B, which are smaller than Sanofi SA quarterly revenues of $8.1B. BioNTech SE's net income of $276.6M is lower than Sanofi SA's net income of $531.9M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Sanofi SA's PE ratio is 19.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.00x versus 2.60x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    7.00x 191.55x $1.3B $276.6M
    SNY
    Sanofi SA
    2.60x 19.96x $8.1B $531.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Down 50%, Is Dell Technologies a Buy?
Down 50%, Is Dell Technologies a Buy?

Dell (NYSE:DELL)’s share price has been on a roller coaster…

How Bad Will the Stock Market Get?
How Bad Will the Stock Market Get?

In recent trading days, global stock markets have seen massive…

Is JOBY Stock a Buy, Sell or Hold?
Is JOBY Stock a Buy, Sell or Hold?

Joby Aviation (NYSE:JOBY) got started with the big idea of…

Stock Ideas

Sell
36
Is MSFT Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 30x

Sell
30
Is AAPL Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 28x

Sell
33
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 33x

Alerts

Buy
55
SLNO alert for Apr 9

Soleno Therapeutics [SLNO] is up 7.3% over the past day.

Sell
20
HELE alert for Apr 9

Helen Of Troy [HELE] is up 10.1% over the past day.

Sell
18
OXM alert for Apr 9

Oxford Industries [OXM] is up 17.72% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock